BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsEarnings

Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are

Related news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-04-29 20:30 EST

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

LENZLenz Therapeutics Inc2026-05-11 20:05 EST

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

EYPTEyePoint Pharmaceuticals2026-05-06 11:00 EST

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

EYPTEyePoint Pharmaceuticals2026-08-05 11:00 EST

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

IRIXIRIDEX2026-05-19 20:05 EST

Iridex Reports First Quarter 2026 Financial Results

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Stock data

Close
65.33 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States